Most coverage of contract pharmacy restrictions is written from the outside. It tracks lawsuits, manufacturer policy announcements, state legislation, and federal uncertainty. All of that matters. None of it tells you what happens inside a health center on the Monday morning after a new policy drops. Thomasyna Sweed knows that Monday well. She is Program […]
Contract Pharmacy Restrictions: 6 Rules That Actually Work Read More »
A multi-state 340B program is a single covered-entity operating model applied across hospitals, clinics, pharmacies, vendors, and state regulatory environments that do not match each other. It scales when the organization standardizes its compliance core, documents every justified local exception, and governs vendors on outcomes rather than service levels. That distinction sits at the center
Multi-State 340B Program Management: How Health Systems Scale Without Losing Control Read More »
Duplicate discount prevention is the process of ensuring a covered entity never claims both a 340B discount and a Medicaid rebate on the same drug unit. It sounds like a narrow compliance task. In practice, it depends on data quality, billing accuracy, Medicaid decisions, vendor processes, and ongoing review working together, which is exactly why
Duplicate Discount Prevention: What Actually Has to Work Behind the Scenes Read More »
What Is the 340B Rebate Model Pilot, and Why Is It Back Now? The 340B rebate model pilot is HRSA’s proposed replacement for upfront 340B discounts. Under this model, for a defined set of drugs, instead of getting the purchase price, covered entities would dispense at full price and then submit a rebate request to
340B Rebate Model Pilot: HRSA’s 2027 Comeback Read More »
340B mission impact is the outcome that results when a covered entity’s leadership makes intentional, defensible, and well-governed decisions about how to allocate 340B savings across competing needs. It is not automatic. Savings only become mission impact when leaders choose where the money goes and can prove why. That distinction sits at the center of
340B Mission Impact: How One Rural Health Center Turns Savings Into Real Patient Care Read More »
What is Care Team Continuous Improvement? Care team continuous improvement is the ongoing, systematic effort to enhance the delivery, coordination, and outcomes of patient care by shifting from crisis-driven responses to proactive, data-informed strategies. In today’s complex healthcare landscape, home care and aging services are facing unprecedented challenges. The volume of aging adults requiring complex
Aging by Design: Protecting Your Family from Cognitive Crises Read More »
Duplicate discounts in 340B have become one of the most consequential issues shaping the program’s future. What once appeared to be a technical compliance concern has evolved into a broader debate about data transparency, manufacturer oversight, Medicaid managed care complexity, and the role of federal regulators. At the center of that debate is a fundamental
Rebate Pilot Blocked: Legal Limits in 340B’s Next Phase Read More »
340B mission impact is the patient and community outcome produced when program savings expand access, reduce pharmacy counter costs, and fund comprehensive safety-net services as Congress intended. It matters because the 340B Drug Pricing Program is increasingly debated as a financial and legal mechanism, while the statutory purpose, to stretch scarce federal resources and reach
Turning 340B Savings into Patient Access: The Mission Impact Debate Read More »
340B claims-level data is the patient- and claim-level information a covered entity uses to determine eligibility, accumulate savings, report performance, and defend program integrity across split billing, contract pharmacy, and supporting vendor systems. It matters because most 340B failures today are not caused by teams misunderstanding policy language, but by inconsistent, incomplete, or unreconciled data
Claims-Level Data Challenges in 340B: Pharmacy & Medical Read More »
340B operational control is the covered entity’s ability to keep core program integrity stable while still running a modern operating model that includes manufacturer-specific requirements, reimbursement mechanics that touch pharmacy and finance, and policy windows that can open, narrow, or pivot faster than internal governance forums can convene. If that definition feels broader than “we
The Reality of 340B Today: From Compliance to Control in a Rapidly Changing Environment Read More »
